Antibody persistence, 32 years after post-exposure prophylaxis with human diploid cell rabies vaccine (HDCV)

Vaccine

Volumn 29, Issue 21, 2011, Pages 3742-3745

  Fayaz, Ahmad ^a   Simani, Susan ^a   Janani, Alireza ^a   Farahtaj, Firouzeh ^a   Biglari, Peyvand ^a   Howeizi, Nader ^a   Eslami, Nasser ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Antibody persistence; Post exposure prophylaxis; Rabies

Indexed keywords

NEUTRALIZING ANTIBODY; RABIES VACCINE;

ADULT; ARTICLE; CLINICAL ARTICLE; HUMAN; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; BITES AND STINGS; CHILD; CHILD, PRESCHOOL; DOGS; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; IRAN; MALE; MIDDLE AGED; POST-EXPOSURE PROPHYLAXIS; RABIES; RABIES VACCINES; RABIES VIRUS; WOLVES; YOUNG ADULT;

EID: 79955080716     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.048     Document Type: Article

References (12)

1. Sikes R.K., Cleary W.F., Koprowsky H., Wiktor T.J., Kaplan M.M. Effective protection of monkeys against death from street virus by post-exposure administration of tissue culture rabies vaccine. Bull. WHO 1971, 45:1-11.
2. Wiktor T.J., Plotkin S., Grella D.W. Human cell culture rabies vaccine: antibody response in man. JAMA 1973, 224:1170-1171.
3. Bahmanyar M. Results of antibody profiles in man vaccinated with HDC-S vaccine with various schedules. Symposium Series on Immunobiological Standards 1974, 21:231-239. Bsil, Karger.
4. Bahmanyar M., Fayaz A., Nour-Salehi S., Bahmanyar M., Koprowski H. Successful protection of humans exposed to rabies infection: post-exposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA 1976, 236:2751-2754.
5. Fayaz A., Simani S., Nour-Salehi S.D., Bahmanyar M. Booster effect of human diploid cell antirabies vaccine in previously treated persons. J Am Med Assoc 1981, 248:2334-2335.
6. Smith J.S., Yager P.A., Baer M.A. Rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus-neutralizing antibody. Laboratory technique in rabies 1996, WHO, Geneva. 4th ed. F.X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
7. Thraenhart O., Kreuzfelder E., Hillebrandt M., Marcus I., Ramakrishnan K., Fu Z.F., Dietzschold B. Long-term humoral and cellular immunity after vaccination with cell culture rabies vaccines. Clin Immunopathol 1994, 71:287-292.
8. Briggs D.J., Schwenke F.J.R. Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccine. Vaccine 1992, 10(2.).
9. Suwansrinon K., Wild H., Benjavongleulchai M., Banjongkasaena U., Lertjarutorn S. Survival of neutralizing antibody in previously rabies vaccinated subjects. Vaccines 2006, 24:3878-3880.
10. Sabchareon A., Chantavanich P., Pasuralertsakul S., Pojjaroen-Anant C., Prarinyanupharb V., Attanath P., et al. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunization with purified Vero cell rabies vaccine. Pediatr Infect Dis J 1998, 17:1001-1007.
11. Strady A., Lang J., Lienard M., Blondeau C., Jaussaud R., Plotkin S.A., et al. Antibody persistence following preexposure regimens of cell culture rabies vaccine: 10-year follow up and proposal for a new booster policy. J Infect Dis 1998, 177:1290-1295.
12. WHO Technical report series 931, WHO Expert Consultation on Rabies, first report 2004: Geneva, Switzerland.